McKesson’s Conference Pitch Highlights Specialty Momentum but Ignores Valuation and Legal Overhang

What happened

McKesson management presented at the Bank of America Global Healthcare Conference on May 12, 2026, likely emphasizing the company’s specialty and oncology growth, ongoing share repurchases, and the Medical-Surgical spin-off. The DeepValue master report, however, underscores a more nuanced reality: oncology segment profit growth has been heavily acquisition-aided and includes one-time gains, while the stock trades at ~32.6x trailing GAAP EPS and ~21x EV/EBITDA, leaving little room for error. Opioid liabilities of $5.7B and a revived West Virginia case pose tail risks that could constrain capital returns. The conference offered no new quantitative disclosures to alter the thesis that the risk-reward skews unfavorable at current levels.

Implication

Long-term investors should wait for a pullback to ~$720 (19x FY26 adjusted EPS) or clearer evidence that oncology profit growth is sustainably organic and opioid liabilities remain manageable before initiating or adding to positions.

Thesis delta

No material change. The conference reaffirmed the existing narrative but provided no new data to challenge the master report’s conclusion that the stock is fully priced. The overall stance remains cautious, with a potential sell recommendation until a better entry point or risk resolution.